| Literature DB >> 34323407 |
Maria Lombardi1, Davide Lazzeroni1, Giulia Benedetti2, Gloria Bertoli3, Dejan Lazarevic4, Michela Riba4, Francesco De Cobelli2, Ornella Rimoldi3, Giulia d'Amati5, Iacopo Olivotto6, Chiara Foglieni1, Paolo Camici1,7.
Abstract
Entities:
Mesh:
Substances:
Year: 2021 PMID: 34323407 PMCID: PMC8287979 DOI: 10.1002/ctm2.435
Source DB: PubMed Journal: Clin Transl Med ISSN: 2001-1326
FIGURE 1NGS analysis of plasma miRs. Venn diagram representation of the plasma miRs up‐/down ‐regulated in HCM patients vs. CTRL by NGS (A) and corresponding scatterplots of principal component analysis (PCA) of patients and controls screened by NGS (B) showing no remarkable discrete clustering of the non‐obstructive HCM (HCM in the panel) vs. obstructive HCM vs. CTRL. Heatmap of the relative expression of miRs differential by NGS displays the existence of finest difference in miR expressions between HCM and CTRL (C)
FIGURE 2Analysis of plasma miRs by RT‐qPCR and in silico engines and association between plasma miRs by RT‐qPCR and left ventricle ejection fraction. Differential plasma miR expression levels in HCM vs. CTRL by RT‐qPCR are plotted (A). Values are presented as boxes (min to max) and dots indicate single sample values. Mann‐Whitney test is applied and significant differences are shown as *p < 0.05 and **p < 0.01, ***p < 0.001, ****p < 0.0001. Receiver‐operator characteristic (ROC) curve analysis of plasma DEmiRs is shown (B). AUC > 0.7 with significant p values was considered as threshold for good discriminant performance. The network obtained by miR TargetLink Human for strong interactions among DEmiRs and their putative target genes is shown (C). Orange nodes show target genes associated with three or more miRs, blue nodes those shared by less than three miRs, brown nodes indicate miRs. The interactions among the proteins encoded by target genes drawn by STRING v11 are presented (D). Nodes corresponding to clustered proteins are presented in the same color. Linear relations between hsa‐miR‐144‐3p and hsa‐miR‐20b‐5p or hsa‐miR‐25‐3p in the plasma samples of HCM population are shown (E). Linear relation between the hsa‐miR‐144‐3p and hsa‐miR‐20b‐5p expression levels determined by RT‐qPCR and the left ventricle ejection fraction (EF) assessed by routine echocardiography or cardiac magnetic resonance in patients either with non obstructive (HCM) or obstructive (HOCM) hypertrophic cardiomyopathy is shown (F)
FIGURE 3Analysis of myocardial tissue miRs by RT‐qPCR and expression of PTEN. The expression levels of DEmiRs determined by RT‐qPCR in the myocardial tissue samples of HCM vs. ctrl are plotted. The miRs down‐regulated in HCM are in A, those upregulated in B. Receiver‐operator characteristic (ROC) curve analysis of tissue DEmiRs is shown (C). AUC > 0.7 with significant p values was considered as threshold for good discriminant performance. The network obtained by miR TargetLink Human for strong interactions among hsa‐miR‐4451, hsa‐miR‐382‐5p, hsa‐miR‐25‐3p, tissue DEmiRs and their putative target genes is presented (D). Orange nodes show target genes associated with three or more miRs, blue nodes those shared by less than three miRs, brown nodes indicate miRs. The corresponding protein network drawn by STRING v11 is shown (E). The upregulation of PTEN gene determined by RT‐qPCR in HCM vs. ctrl tissues is plotted, (F). Representative qualitative evaluation of the protein presence into myocardial tissues from two HCMs and one ctrl by western blot (G, up) is shown. Immunofluorescence images of HCM and ctrl cryosections are displayed (G, down) and PTEN quantification by specific ELISA is plotted (H). Values In A, B, F, and H plots are presented as boxes (min to max), and dots indicate single sample values. Mann‐Whitney test is applied and significant differences are shown as *p < 0.05
FIGURE 4Schematic representation of the study results
DEmiRs: Comparison with published studies
| Plasma | Myocardial tissue | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HCM (our study) | CAD | HF | AF | AMI | other pathologies | HCM (our study) | other pathologies | References_DOI | References_full citation | |
| miR‐19a | UP | UP | UP (chronic Chagas disease) | NDE | UP (chronic Chagas disease) |
|
Nonaka, C.K.V. et al, Circulating miRNAs as Potential Biomarkers Associated with Cardiac Remodeling and Fibrosis in Chagas Disease Cardiomyopathy. International journal of molecular sciences, 20. | |||
|
|
Mansouri, F. and Seyed Mohammadzad, M.H. Molecular miR‐19a in Acute Myocardial Infarction: Novel Potential Indicators of Prognosis and Early Diagnosis. Asian Pacific journal of cancer prevention: APJCP, 21, 975–982. | |||||||||
|
|
Zhong, J. et al, Circulating microRNA‐19a as a potential novel biomarker for diagnosis of acute myocardial infarction. International journal of molecular sciences, 15, 20355–20364. | |||||||||
|
|
Gao, F. et al, Therapeutic role of miR‐19a/19b in cardiac regeneration and protection from myocardial infarction. Nature communications, 10, 1802. | |||||||||
| miR‐20b | UP | DOWN (T2DM) | NDE |
|
Wander, P.L. et al, Short Report: Circulating microRNAs are associated with incident diabetes over 10 years in Japanese Americans. Scientific reports, 10, 6509. | |||||
|
|
Zampetaki, A. et al, Plasma microRNA profiling reveals loss of endothelial miR‐126 and other microRNAs in type 2 diabetes. Circulation research, 107, 810–817. | |||||||||
|
|
Zhou, J.et al, microRNA expression profiling of heart tissue during fetal development. International journal of molecular medicine, 33, 1250–1260. | |||||||||
| miR‐29b | UP | UP | UP (chronic Chagas disease) | NDE | UP (chronic Chagas disease, arrythmogenic right ventricle cardiomyopathy) |
|
Nonaka, C.K.V. et al, Circulating miRNAs as Potential Biomarkers Associated with Cardiac Remodeling and Fibrosis in Chagas Disease Cardiomyopathy. International journal of molecular sciences, 20. | |||
|
|
Yang, Q. et al, Aberrant expression of miR‐29b‐3p influences heart development and cardiomyocyte proliferation by targeting NOTCH2. Cell proliferation, 53, e12764. | |||||||||
| miR‐126 | UP | DOWN | UP | UP | UP | DOWN (T2DM, chronic renal disease) | NDE |
|
Wang, X. et al, Expression of miR‐126 and its potential function in coronary artery disease. African health sciences, 17, 474–480. | |
|
|
Li, H.Y. et al, Plasma MicroRNA‐126‐5p is Associated with the Complexity and Severity of Coronary Artery Disease in Patients with Stable Angina Pectoris. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology, 39, 837–846. | |||||||||
|
|
Fourdinier, O. et al, Serum levels of miR‐126 and miR‐223 and outcomes in chronic kidney disease patients. Scientific reports, 9, 4477. | |||||||||
| miR‐144 | UP | UP | UP | UP (arrythmogenic right ventricle cardiomyopathy) | DOWN | UP (arrythmogenic right ventricle cardiomyopathy) |
|
de Gonzalo‐Calvo, D. et al, Epigenetic Biomarkers and Cardiovascular Disease: Circulating MicroRNAs. Revista espanola de cardiologia (English ed.), 70, 763–769. | ||
|
|
Bye, A. et al, Circulating microRNAs predict future fatal myocardial infarction in healthy individuals ‐ The HUNT study. Journal of molecular and cellular cardiology, 97, 162–168. | |||||||||
|
|
Abu‐Halima, M. et al, Micro‐RNA signatures in monozygotic twins discordant for congenital heart defects. PloS one, 14, e0226164. | |||||||||
|
|
Song, L. et al, MiR‐451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. Journal of cellular and molecular medicine, 18, 2266–2274. | |||||||||
| miR‐182 | DOWN | UP | UP | UP (arrythmogenic right ventricle cardiomyopathy) | NDE | DOWN (arrythmogenic right ventricle cardiomyopathy) |
|
Taurino, C. et al, Gene expression profiling in whole blood of patients with coronary artery disease. Clinical science (London, England : 1979), 119, 335–343. | ||
|
|
Cakmak, H.A. et al, The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome‐wide expression study. Journal of cardiovascular medicine (Hagerstown, Md.), 16, 431–437. | |||||||||
|
|
Li, N. et al, miR‐182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in Heart. Scientific reports, 6, 21228. | |||||||||
| miR‐223 | NDE | DOWN |
|
Barsanti, C. et al, Differential regulation of microRNAs in end‐stage failing hearts is associated with left ventricular assist device unloading. BioMed research international, 2015, 592512. | ||||||
| miR‐223 (Cont.) |
|
Chuang, T.Y. et al, MicroRNA‐223 Expression is Upregulated in Insulin Resistant Human Adipose Tissue. Journal of diabetes research, 2015, 943659. | ||||||||
|
|
Lu, H., Buchan, R.J. and Cook, S.A., MicroRNA‐223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovascular research, 86, 410–420. | |||||||||
| miR‐374b | NDE | DOWN | UP (STEMI vs. NSTEMI) | UP | DOWN (calcific aortic stenosis: valves) |
|
Ward, J.A. et al, Circulating Cell and Plasma microRNA Profiles Differ between Non‐ST‐Segment and ST‐Segment‐Elevation Myocardial Infarction. Family medicine & medical science research, 2, 108. | |||
|
|
Xu, H.X. et al, Differential Expression of MicroRNAs in Calcific Aortic Stenosis. Clinical laboratory, 63, 1163–1170. | |||||||||
| miR‐451a | NDE | NDE | DOWN |
| Song, L. et al, MiR‐451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. Journal of cellular and molecular medicine, 18, 2266–2274. | |||||
| miR‐454 | DOWN | UP (DCM in children) *** | NDE |
| Enes Coşkun, M. et al, Plasma microRNA profiling of children with idiopathic dilated cardiomyopathy. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals, 21, 56–61. | |||||
| miR‐4485 | NDE | UP | / | / | ||||||
| miR‐4732 | UP | UP (congenital heart defetcs) | NA |
| Abu‐Halima, M .et al, Micro‐RNA signatures in monozygotic twins discordant for congenital heart defects. PloS one, 14, e0226164. | |||||
LEGEND: NDE, not differentially expressed vs. ctrl; UP, up‐regulated; DOWN, down‐regulated; NA, undetermined by RT‐qPCR.